| 1 |
Tas F, Ozturk A, Erturk K. Primary tumor SUV(max) and ratio of SUV(max) to primary tumor size on pretreatment 18F-FDG-PET/CT scan in small cell lung cancer : Which is superior for the prognosis? Wien Klin Wochenschr 2023. [PMID: 36882606 DOI: 10.1007/s00508-023-02160-0] [Reference Citation Analysis]
|
| 2 |
Dumoulin DW, Bironzo P, Passiglia F, Scagliotti GV, Aerts JGJV; ERN-LUNG Core Network Mesothelioma. Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours. Eur Respir Rev 2023;32. [PMID: 36754434 DOI: 10.1183/16000617.0174-2022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Park H, Tseng SC, Sholl LM, Hatabu H, Awad MM, Nishino M. Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications. Radiology 2022;305:512-25. [PMID: 36283111 DOI: 10.1148/radiol.220585] [Reference Citation Analysis]
|
| 4 |
Hu Y, Sun J, Li D, Li Y, Li T, Hu Y. The combined role of PET/CT metabolic parameters and inflammatory markers in detecting extensive disease in small cell lung cancer. Front Oncol 2022;12:960536. [DOI: 10.3389/fonc.2022.960536] [Reference Citation Analysis]
|
| 5 |
Novruzov E, Mori Y, Antke C, Dabir M, Schmitt D, Kratochwil C, Koerber SA, Haberkorn U, Giesel FL. A Role of Non-FDG Tracers in Lung Cancer? Semin Nucl Med 2022:S0001-2998(22)00054-X. [PMID: 35803770 DOI: 10.1053/j.semnuclmed.2022.05.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Sherry V. Lung cancer: Prevention and early identification are key. Nurse Pract 2022;47:42-7. [PMID: 35758920 DOI: 10.1097/01.NPR.0000832548.88417.be] [Reference Citation Analysis]
|
| 7 |
Kandathil A, Subramaniam RM. FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. Semin Nucl Med 2022:S0001-2998(22)00048-4. [PMID: 35738910 DOI: 10.1053/j.semnuclmed.2022.04.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Vaz SC, Adam JA, Bolton RCD, Vera P, van Elmpt W, Herrmann K, Hicks RJ, Lievens Y, Santos A, Schöder H, Dubray B, Visvikis D, Troost EGC, de Geus-Oei LF. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. Eur J Nucl Med Mol Imaging 2022. [PMID: 35022844 DOI: 10.1007/s00259-021-05624-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 9 |
Giammarile F, Pellet O, Calapaquí Terán AK, Delgado Bolton RC. PET imaging of lung and pleural cancer. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00206-4] [Reference Citation Analysis]
|
| 10 |
Kukava S, Baramia M. Place and Role of PET/CT in the Diagnosis and Staging of Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_303] [Reference Citation Analysis]
|
| 11 |
Martin SS, Muscogiuri E, Burchett PF, van Assen M, Tessarin G, Vogl TJ, Schoepf UJ, De Cecco CN. Tumorous tissue characterization using integrated 18F-FDG PET/dual-energy CT in lung cancer: Combining iodine enhancement and glycolytic activity. Eur J Radiol 2021;:110116. [PMID: 34996651 DOI: 10.1016/j.ejrad.2021.110116] [Reference Citation Analysis]
|
| 12 |
Oprea-Lager DE, Cysouw MCF, Boellaard R, Deroose CM, de Geus-Oei LF, Lopci E, Bidaut L, Herrmann K, Fournier LS, Bäuerle T, deSouza NM, Lecouvet FE. Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Front Oncol 2021;11:772530. [PMID: 34869009 DOI: 10.3389/fonc.2021.772530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Lee SJ, Ha S, Pahk K, Choi YY, Choi JY, Kim S, Kwon HW. Changes in treatment intent and target definition for preoperative radiotherapy after 18F-Fluorodeoxyglucose positron emission tomography in rectal cancer: A Meta-analysis. Eur J Radiol 2021;145:110061. [PMID: 34839213 DOI: 10.1016/j.ejrad.2021.110061] [Reference Citation Analysis]
|
| 14 |
Treglia G, Sadeghi R, Giovinazzo F, Galiandro F, Annunziata S, Muoio B, Kroiss AS. PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses. Cancers (Basel) 2021;13:5172. [PMID: 34680321 DOI: 10.3390/cancers13205172] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 15 |
Chai Y, Ma Y, Feng W, Lu H, Jin L. Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation. World J Surg Oncol 2021;19:258. [PMID: 34461929 DOI: 10.1186/s12957-021-02364-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 16 |
Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D, Van Schil PE, Vansteenkiste J, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 2021;32:839-53. [PMID: 33864941 DOI: 10.1016/j.annonc.2021.03.207] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 34.5] [Reference Citation Analysis]
|
| 17 |
Makino T, Izumi K, Mizokami A. Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment. Biomedicines 2021;9:414. [PMID: 33921329 DOI: 10.3390/biomedicines9040414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 18 |
Couñago F, de la Pinta C, Gonzalo S, Fernández C, Almendros P, Calvo P, Taboada B, Gómez-Caamaño A, Guerra JLL, Chust M, González Ferreira JA, Álvarez González A, Casas F. GOECP/SEOR radiotherapy guidelines for small-cell lung cancer. World J Clin Oncol 2021; 12(3): 115-143 [PMID: 33767969 DOI: 10.5306/wjco.v12.i3.115] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Quartuccio N, Salem A, Laudicella R, Spataro A, Chiaravalloti A, Caobelli F, Cistaro A, Alongi P, Evangelista L. The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. Nucl Med Commun 2021;42:839-45. [PMID: 33741854 DOI: 10.1097/MNM.0000000000001407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Hirata K, Tamaki N. Quantitative FDG PET Assessment for Oncology Therapy. Cancers (Basel) 2021;13:869. [PMID: 33669531 DOI: 10.3390/cancers13040869] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 21 |
Zhang Q, Cui Q. Biodistribution of andrographolide to assess the interior-exterior relationship between the lung and intestine using microPET. Thorac Cancer 2020;11:3365-74. [PMID: 33017514 DOI: 10.1111/1759-7714.13682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
